

PRESS NEWS

Gradientech receives SEK 6.3M from BIO-X® Accelerate program

Uppsala, March 27, 2020. Gradientech has been awarded with SEK 6.3M from the highly competitive BIO-X Accelerate program, to support the commercialization journey of its diagnostic system QuickMIC®. QuickMIC is an ultra-rapid system designed to provide fast and targeted treatment for sepsis patients.

In the challenging times we are facing, the need for innovative, life-saving infection diagnostics is higher than ever before. Due to the emergence of the new coronavirus (COVID-19) pandemic, older people and those with chronic conditions are now at a higher risk of contracting severe illnesses like sepsis. The survival of sepsis patients is time critical, where every minute without appropriate treatment increases the risk of dying. QuickMIC determines which antibiotic treatment will be most effective for sepsis patients in record time.

“The funding received from the BIO-X Accelerate program will definitely help us towards a faster market introduction of the QuickMIC system, both by advancing the production transfer process of our antibiotic panels, and by securing our clinical performance evaluation” – says Teresa Fernandez Zafra, PhD, Product Manager at Gradientech. The clinical evidence gathered in the proposed project will open the QuickMIC system to CE-IVD marking, which is crucial to establish the system in standard clinical practice.

For further information, please contact:

Sara Thorslund, PhD, CEO Gradientech

Tel: +46 736 29 35 80, email: sara.thorslund@gradientech.se

TO THE EDITORS

About Gradientech AB (publ)

Gradientech is a Swedish biotech and diagnostic company focusing on innovative microfluidic product development. We provide systems for high-quality analysis of cell behaviour in response to gradients of biomolecules. Gradientech is currently developing QuickMIC®, an ultra-rapid system for antibiotic susceptibility testing. QuickMIC is designed to offer personalized treatment options for sepsis patients, thereby contributing to increased survival, reduced healthcare costs and lower antibiotic resistance.

www.gradientech.se

About the BIO-X® Accelerate program

BIO-X Accelerate is a further development of BIO-X in close collaboration with Tillväxtverket and Region Uppsala, with Uppsala Innovation Centre as partner, with the goal to accelerate the development of innovative life-science companies in the region.



About QuickMIC

QuickMIC is a unique diagnostic system for ultra-rapid antibiotic susceptibility testing of positive blood culture samples from sepsis patients. It's an easy to use and scalable system, well-suited for small and larger clinical laboratories. Each instrument module analyses one sample against a panel of multiple antibiotics, optimized for either Gram-positive and Gram-negative bacteria. MIC-values are reported in as short as 2 hours, making it the most rapid diagnostic system for phenotypic antibiotic susceptibility testing. www.quickmic.se

